Similarly, the ExteNET (Extended Adjuvant Treatment of Breast Cancer With Neratinib) trial46 showed that adjuvant neratinib given after adjuvant trastuzumab improved invasive disease-free survival, from 88% to 90% (P = .008), compared with placebo, but there are no studies, to our knowledge, on how adjuvant neratinib may alter outcomes in patients with residual disease after neoadjuvant, ERBB2-targeted therapy. Here, ERBB2 is linked to breast cancer.